Literature DB >> 1616860

Oestrogen receptor negative-progesterone receptor positive phenotype in 1,211 breast tumours.

M F Pichon1, E Milgrom.   

Abstract

From 1,211 breast cancers, 15 oestrogen receptor (ER) negative-progesterone receptor (PgR) positive breast cancers by conventional dextran coated charcoal steroid binding assays in cytosol were reassessed using Elisa techniques with monoclonal antireceptors antibodies in the cytosolic and nuclear fractions, and immunocytochemistry on cryostat sections. Three categories of results were found in this series. Two tumours were false negative ER due to receptor sites occupancy by hormonal contraceptive treatment. A second group of ten tumours, with high PgR concentrations and immunoreactive ER, corresponds to non ER-binding forms of receptors. One PgR positive tumour was found to be devoid of PgR by using monoclonal antiPgR antibodies might contain a progesterone binding cyst protein. Only two tumours were found to be true ER negative-PgR positive by all methods. This rare phenotype deserves further study of the regulation of the PgR gene.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1616860      PMCID: PMC1977767          DOI: 10.1038/bjc.1992.187

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF-7 breast cancer cells.

Authors:  A Berkenstam; H Glaumann; M Martin; J A Gustafsson; G Norstedt
Journal:  Mol Endocrinol       Date:  1989-01

2.  Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy.

Authors:  R A McClelland; U Berger; L S Miller; T J Powles; R C Coombes
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

3.  Origin of the high constitutive level of progesterone receptor in T47-D breast cancer cells.

Authors:  J F Savouret; F Fridlanski; M Atger; M Misrahi; R Berger; E Milgrom
Journal:  Mol Cell Endocrinol       Date:  1991-02       Impact factor: 4.102

4.  Quantitative immunological detection of estrogen receptors in nuclear pellets from human breast cancer biopsies.

Authors:  S M Thorpe; A E Lykkesfeldt; A Vinterby; M Lonsdorfer
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

5.  Progesterone-binding cyst protein in human breast tumor cytosol.

Authors:  O A Lea; S Kvinnsland; T Thorsen
Journal:  Cancer Res       Date:  1987-12-01       Impact factor: 12.701

6.  Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor.

Authors:  A M Sarrif; J R Durant
Journal:  Cancer       Date:  1981-09-01       Impact factor: 6.860

7.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity.

Authors:  S A Fuqua; S D Fitzgerald; G C Chamness; A K Tandon; D P McDonnell; Z Nawaz; B W O'Malley; W L McGuire
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

8.  Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors.

Authors:  M Perrot-Applanat; M T Groyer-Picard; F Lorenzo; A Jolivet; M T Vu Hai; C Pallud; F Spyratos; E Milgrom
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

9.  Breast cancers negative for estrogen receptor but positive for progesterone receptor, a true entity?

Authors:  D T Kiang; R Kollander
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

  9 in total
  2 in total

1.  Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity?

Authors:  Jawad Kiani; Afrasyab Khan; Hina Khawar; Fawad Shuaib; Shahid Pervez
Journal:  Pathol Oncol Res       Date:  2006-12-25       Impact factor: 3.201

2.  Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.

Authors:  S Detre; N King; J Salter; K MacLennan; J A McKinna; M Dowsett
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.